Stay updated on Filgotinib Alone and With MTX in Rheumatoid Arthritis Clinical Trial
Sign up to get notified when there's something new on the Filgotinib Alone and With MTX in Rheumatoid Arthritis Clinical Trial page.

Latest updates to the Filgotinib Alone and With MTX in Rheumatoid Arthritis Clinical Trial page
- Check4 days agoChange DetectedThe page now shows Revision: v3.6.3. Topic and tag entries for Rheumatoid arthritis and MedlinePlus Genetics were removed, along with the older Revision: v3.6.2 tag.SummaryDifference0.1%

- Check12 days agoChange DetectedThe revision label on the page has been updated to v3.6.2, replacing the previous v3.6.0. This reflects a minor backend update to the site; no study content or user-facing features are indicated to have changed.SummaryDifference0.0%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedRecruitment status now shows 'No longer looking for participants', signaling that enrollment is closed. The page adds new help sections (How to Read a Study Record, Common Questions, How to Join a Study) and updates the Intervention/Treatment heading and revision label to v3.6.0 to reflect the updated documentation.SummaryDifference0.2%

- Check33 days agoChange DetectedPage revision updated from v3.5.4 to v3.5.5. This indicates a new version of the page, likely for minor updates or maintenance rather than substantive content changes.SummaryDifference0.0%

- Check48 days agoChange DetectedLakefront Biotherapeutics NV was added as a collaborator, and Galapagos NV was removed from the collaborators list.SummaryDifference0.0%

- Check55 days agoChange DetectedThe Revision label was updated from v3.5.3 to v3.5.4. This indicates a new version of the page resources used for the study details.SummaryDifference0.0%

Stay in the know with updates to Filgotinib Alone and With MTX in Rheumatoid Arthritis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Filgotinib Alone and With MTX in Rheumatoid Arthritis Clinical Trial page.